Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2

Conditions

Plasmacytoma 2Paraproteinemias 2Multiple Myeloma 2Leukemia, Plasma Cell 2Patient Preference 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leiomyoma 1Inflammatory Breast Neoplasms 1Breast Neoplasms 1Agnosia 1Advanced Solid Tumors 1Advanced Cancer 1Abdominal Cancer 1

Interventions

fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 6Melphalan 6Whole-Body Irradiation 5Tacrolimus 5Mycophenolic Acid 5Dexamethasone 4Cyclophosphamide 4fludarabine 3filanesib 3Bortezomib 3ixazomib 2Steroids 2Sirolimus 2Lenalidomide 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Cytarabine 2Carmustine 2Antilymphocyte Serum 2pomalidomide 1merphos 1elotuzumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carmustine, poliferprosan 20 drug combination 1carfilzomib 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Leukemia, Plasma Cell × Injections, Subcutaneous × Clear all
NCT00821249 2020-10-19

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Pfizer

Phase 1/2 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡